Inventiva (IVA) Projected to Post Quarterly Earnings on Wednesday

Inventiva (NASDAQ:IVA - Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, March 26th. Analysts expect Inventiva to post earnings of ($0.43) per share for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.

Inventiva Trading Down 2.0 %

IVA traded down $0.06 during midday trading on Friday, reaching $2.88. 317 shares of the company's stock traded hands, compared to its average volume of 63,732. Inventiva has a 52 week low of $1.53 and a 52 week high of $3.98. The firm has a fifty day moving average of $2.63 and a two-hundred day moving average of $2.46.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Stifel Nicolaus reduced their price objective on shares of Inventiva from $20.00 to $17.00 and set a "buy" rating on the stock in a research report on Friday, November 22nd. HC Wainwright reissued a "buy" rating and set a $13.00 price target on shares of Inventiva in a research report on Thursday, January 30th. Finally, TD Cowen assumed coverage on Inventiva in a research report on Friday, February 21st. They issued a "buy" rating and a $10.00 price target for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $12.60.

Remove Ads

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.